Compare DuPont de Nemours Inc (DD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? DuPont de Nemours Inc trades at $132.05 (market cap $17.70B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.2× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays a 1.83% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DD | VRTX | |
|---|---|---|
Market Cap | $17.70B | $128.16B |
Volume | 638,303 | 806,603 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $557.96 |
52-Week Low | $92.49 | $407.37 |
Typical Hold Time | 89 Days | 120 Days |
Enterprise Value | $19.09B | $122.29B |
Dividend Yield | 1.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, down 0.6% for the day, with neutral technical signals and mixed fundamentals. The company has beaten earnings estimates for three consecutive quarters but shows declining revenue and negative net income for 2025. Recent innovations include digital tools for sugar separation and sustainable Tyvek materials, while facing legal settlements over PFAS contamination.
Outlook remains cautious with analyst consensus favoring Buy (58.5%) but a price target of $95 below current levels. Key opportunities include margin expansion in healthcare and water technologies, while risks involve ongoing litigation costs, uneven construction demand, and profitability challenges despite recent earnings beats.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
